英格兰的NHS开始为KIMMTRAK提供资金,这是对罕见眼癌尿皮瘤的一种新治疗。 NHS in England begins funding KIMMTRAK, a new treatment for rare eye cancer uveal melanoma.

Immunocore的KIMMTRAK已经获得英格兰国民保健体系的批准,为患有罕见的眼癌,即乳腺黑瘤的成年人提供资金。 Immunocore's KIMMTRAK has been approved for funding by the NHS in England for adults with a rare form of eye cancer, uveal melanoma. 这种治疗对于具有特定基因标记的人有效,是使这种癌症存活下去的第一个治疗,这种癌症往往发展到转移阶段。 This treatment, effective for those with a specific genetic marker, is the first to extend survival for this cancer, which often progresses to a metastatic stage. KIMMTRAK的核准是在Immunocore成功呼吁之后作出的,现在可通过国民保健制度的资金获得。 KIMMTRAK's approval follows a successful appeal by Immunocore and is now available through NHS funding.